Last updated 2 months ago

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

14000 patients around the world
Available in United States, Argentina
The purpose of this study is to evaluate inclisiran sodium 300 mg s.c. (equivalent to 284 mg inclisiran) compared to placebo on reducing the risk of 4P-MACE in adult patients at high risk for their first major adverse cardiovascular event. Randomized participants will receive study medication (inclisiran or placebo), administered s.c. on Day 1, Day 90, then every 6 months thereafter. This is an event-driven study. Therefore, the study will continue until the required number of clinical events have occurred across both treatment arms, and all participants have a minimum of 3 years of follow-up during the double-blind treatment period.
Novartis Pharmaceuticals
1Research sites
14000Patients around the world
This study is for people with
Cardiovascular disease
Established cardiovascular disease
Requirements for the patient
To 79 Years
All Gender
Medical requirements
Sites
Instituto de Investigaciones Clínicas Mar del Plata
Instituto de Investigaciones Clínicas Mar del Plata
Recruiting
Av. Colón 3456, Mar del Plata, Buenos Aires
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy